Pre-made Afelimomab benchmark antibody (Fab Fusion, anti-TNF therapeutic antibody, Anti-DIF/TNFSF2/TNLG1F Antibody) for drug discovery and mechanism of action (MOA) research

Pre-made Afelimomab benchmark antibody (Fab Fusion, anti-TNF therapeutic antibody, Anti-DIF/TNFSF2/TNLG1F Antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Afelimomab (MAK 195F) is an anti-TNFα monoclonal antibody. Administration of afelimomab reduces the concentration of interleukin-6 in patients with sepsis, but reduces mortality only marginally.[1][2]

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-INN-721-1mg	1mg	3090
GMP-Bios-INN-721-10mg	10mg	Inquiry
GMP-Bios-INN-721-100mg	100mg	Inquiry
GMP-Bios-INN-721-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Afelimomab Biosimilar, Fab Fusion, Anti-Tnf Antibody: Anti-DIF/TNFSF2/TNLG1F therapeutic antibody
INN Name	Afelimomab
Target	TNF
Format	Fab Fusion
Derivation	Mus musculus
Species Reactivity	human
CH1 Isotype	F(ab')2 - G3 - kappa
VD LC	F(ab')2 - G3 - kappa
Highest_Clin_Trial (Jan '20)
Est. Status
100% SI Structure
99% SI Structure
95-98% SI Structure
Year Proposed
Year Recommended
Companies	Abbott Laboratories (Abbott Park IL USA) / Knoll Pharmaceutical (Mount Olive NJ USA)
Conditions Approved
Conditions Active
Conditions Discontinued
Development Tech	0